We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
Read MoreHide Full Article
In the latest close session, Humacyte, Inc. (HUMA - Free Report) was up +1.28% at $0.41. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day. Elsewhere, the Dow gained 0.69%, while the tech-heavy Nasdaq added 1.05%.
Coming into today, shares of the company had lost 30.34% in the past month. In that same time, the Medical sector gained 3.5%, while the S&P 500 gained 0.97%.
The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report. The company's upcoming EPS is projected at -$0.09, signifying a 35.71% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $0.86 million, up 14.67% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.4 per share and a revenue of $4.05 million, signifying shifts of -53.85% and +98.48%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Humacyte, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
In the latest close session, Humacyte, Inc. (HUMA - Free Report) was up +1.28% at $0.41. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day. Elsewhere, the Dow gained 0.69%, while the tech-heavy Nasdaq added 1.05%.
Coming into today, shares of the company had lost 30.34% in the past month. In that same time, the Medical sector gained 3.5%, while the S&P 500 gained 0.97%.
The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report. The company's upcoming EPS is projected at -$0.09, signifying a 35.71% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $0.86 million, up 14.67% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.4 per share and a revenue of $4.05 million, signifying shifts of -53.85% and +98.48%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Humacyte, Inc. is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.